Source: The Laurinburg Exchange
Published: February 1, 2022
CIMS Partner Center: CareSouth Carolina
CareSouth Carolina began giving Monoclonal Antibody IV Therapy (mAB) treatments at its Hartsville Suite B office on January 27, 2021 and since that point has provided more than 7,889 infusions.
The goal of this therapy is to decrease hospitalizations & emergency room visits due to symptoms of COVID-19 and to prevent the patient from progressing to severe disease. This treatment is also used to prevent potential long-term damage from COVID-19.
CareSouth Carolina Hartsville Provider Jennifer Lynch, FNP-C, who oversees the mAB team, said the group has worked hard to make a difference in the community and are thankful for the opportunity to play an important role in fighting COVID-19.
“The monoclonal team at CareSouth may be small, but for the past year, we have made some great strides in outpatient treatment therapeutics for patients who are positive for COVID-19,” Lynch said. “As we reflect on the last year and the patients we have treated with monoclonal antibody infusion we are continually thankful for this opportunity and our role in treating COVID-19 patients. We are proud that we are one of the largest clinics in the countries that provides this type of outpatient treatment. We will continue to follow the latest evidence-based research and bring our patients the most effective and safest treatment therapeutics for COVID-19. The therapy is an hour-long IV infusion that has been developed for the treatment and prophylaxis of viral infections, like COVID-19.”